Markets:

Overview

News

Currencies

International

Treasuries

AIM ImmunoTech Inc. Common Stock (NY:AIM)

0.2643 -0.0211 (-7.39%)

Streaming Delayed Price Updated: 3:56 PM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AIM ImmunoTech Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >

26 Stocks Moving in Thursday's Pre-Market Session ↗

April 21, 2022

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday. Clarus Therapeutics Holdings, Inc. (NASDAQ:...

Via Benzinga

54 Biggest Movers From Yesterday ↗

April 20, 2022

Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...

Via Benzinga

FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer ↗

March 16, 2022

Via Benzinga

Earnings Scheduled For November 11, 2021 ↗

November 11, 2021

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 19, 2022

Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 14, 2022

The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!

Via InvestorPlace

AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting ↗

April 11, 2022

AIM ImmunoTech Inc (NYSE: AIM) has

Via Benzinga

AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer ↗

March 09, 2022

AIM ImmunoTech Inc (NYSE: AIM) announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic...

Via Benzinga

AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses ↗

September 30, 2021

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis...

Via Benzinga

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease ↗

September 28, 2021

AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two...

Via Benzinga

AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients ↗

September 21, 2021

AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive...

Via Benzinga

AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction ↗

September 08, 2021

AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential...

Via Benzinga

Earnings Scheduled For August 13, 2021 ↗

August 13, 2021

Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd...

Via Benzinga

Earnings Scheduled For May 14, 2021 ↗

May 14, 2021

Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report...

Via Benzinga

AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study ↗

April 07, 2021

AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.